Literature DB >> 15287028

Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.

Gary A Ulaner1, Andrew R Hoffman, Jesse Otero, Hsuan-Ying Huang, Zhiquan Zhao, Madhu Mazumdar, Richard Gorlick, Paul Meyers, John H Healey, Marc Ladanyi.   

Abstract

Two types of telomere maintenance mechanisms (TMMs) have been described in human tumors: telomerase activation and alternative lengthening of telomeres (ALT). Although the vast majority of epithelial tumors rely on telomerase activation, many mesenchymal tumors rely on ALT for telomere maintenance, but within this tumor group, the TMMs used by translocation-associated sarcomas have not been systematically studied. We studied telomere lengths and telomerase expression and activity in 30 uncultured tumor samples and in 10 cell lines of Ewing's sarcoma, a prototypical translocation-associated sarcoma, and compared the data to an identical analysis of 60 osteosarcomas, the most common type of sarcoma lacking a specific translocation. Telomerase activity was demonstrated in 21 Ewing's sarcoma tumor samples (70%) and in 9 of 10 Ewing's sarcoma cell lines. Evidence of ALT, indicated by the presence of long and heterogeneous telomeres, was observed only in the cell line without telomerase activity and in none of the 30 Ewing's sarcoma tumor samples. The 9 Ewing's sarcoma patients whose tumors lacked detectable telomerase activity did not differ significantly from the remaining patients in age, stage, EWSR1-FLI1 fusion type, prevalence of TP53 point mutations, or overall survival. The low prevalence of ALT in Ewing's sarcoma contrasted sharply with our data on TMMs in 60 osteosarcomas, which showed ALT in 38 of 60 cases (P<0.0001). The present study, together with emerging published data on other sarcoma types, suggests that a predominance of telomerase activation in the absence of ALT may characterize sarcomas with specific chromosomal translocations (such as Ewing's sarcoma), whereas a high prevalence of ALT appears typical of sarcomas with nonspecific complex karyotypes (such as osteosarcoma). Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15287028     DOI: 10.1002/gcc.20074

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  28 in total

1.  TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression.

Authors:  Kyle Lafferty-Whyte; Alan Bilsland; Stacey F Hoare; Sharon Burns; Nadia Zaffaroni; Claire J Cairney; William Nicol Keith
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

Review 2.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

3.  Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Authors:  Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603

4.  Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

Authors:  Christopher M Heaphy; Andrea P Subhawong; Seung-Mo Hong; Michael G Goggins; Elizabeth A Montgomery; Edward Gabrielson; George J Netto; Jonathan I Epstein; Tamara L Lotan; William H Westra; Ie-Ming Shih; Christine A Iacobuzio-Donahue; Anirban Maitra; Qing K Li; Charles G Eberhart; Janis M Taube; Dinesh Rakheja; Robert J Kurman; T C Wu; Richard B Roden; Pedram Argani; Angelo M De Marzo; Luigi Terracciano; Michael Torbenson; Alan K Meeker
Journal:  Am J Pathol       Date:  2011-09-01       Impact factor: 4.307

5.  The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.

Authors:  Yafang Hu; Daniel Bobb; Jianping He; D Ashley Hill; Jeffrey S Dome
Journal:  Cancer Biol Ther       Date:  2015-04-28       Impact factor: 4.742

6.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

7.  TERT promoter mutations are rare in bone and soft tissue sarcomas of Japanese patients.

Authors:  Tsuyoshi Saito; Keisuke Akaike; Aiko Kurisaki-Arakawa; Midori Toda-Ishii; Kenta Mukaihara; Yoshiyuki Suehara; Tatsuya Takagi; Kazuo Kaneko; Takashi Yao
Journal:  Mol Clin Oncol       Date:  2015-11-09

8.  Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.

Authors:  Jau-Yu Liau; Jen-Chieh Lee; Jia-Huei Tsai; Ching-Yao Yang; Tsung-Lin Liu; Zhi-Long Ke; Hung-Han Hsu; Yung-Ming Jeng
Journal:  Mod Pathol       Date:  2015-10-02       Impact factor: 7.842

9.  ALTernative Telomere Maintenance and Cancer.

Authors:  Robert L Dilley; Roger A Greenberg
Journal:  Trends Cancer       Date:  2015-10-01

10.  A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT.

Authors:  K Lafferty-Whyte; C J Cairney; M B Will; N Serakinci; M-G Daidone; N Zaffaroni; A Bilsland; W N Keith
Journal:  Oncogene       Date:  2009-08-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.